Insider · CIK 0001087939

BAKER JULIAN

Reports to the SEC for 50 companies · NEW YORK, NY

sec.gov

Transactions

Companies

Filings

CIK

0001087939

Summary

Julian C. Baker

Updated Dec 21, 2025

Julian C. Baker is a managing member of Baker Bros. Advisors LP and a long‑time investor in life‑sciences companies. SEC filings and proxy statements list him as a director or reporting person on multiple public biotech issuers and as a significant beneficial owner through Baker Bros. funds.^[1]

Career Background

Cofounder and managing member of Baker Bros. Advisors LP, a New York‑based investment adviser focused on life‑sciences investing.^[1]
Longstanding portfolio manager and investor in biotechnology companies; career origins include roles at Tisch Financial Management and the private equity arm of Credit Suisse First Boston, as noted in company proxy disclosures.^[2]
Frequently appears in Section 16 filings (Forms 3/4/5) and Schedule 13 filings as a reporting person through Baker Bros. funds, reflecting active governance and ownership roles across multiple issuers.^[3]

Current Positions

Director and significant investor — XOMA Royalty Corporation (ticker: XOMA) and related securities, as reflected in the company’s SEC filings identifying Baker Bros. / affiliated reporting persons.^[4]
Significant beneficial owner reported for Heron Therapeutics, Inc. (ticker: HRTX) in Schedule 13G/A filings naming Baker Bros. Advisors and Julian C. Baker.^[5]
Reporting person / beneficial owner filings for Neurogene / Neurogene‑related entities show Baker Bros. and Julian C. Baker listed in Schedule 13 filings.^[6]

SEC Filing Context

Acts as a reporting person on numerous Form 4 and Schedule 13 filings through Baker Bros. entities; filings commonly reflect director deputization or beneficial ownership disclosed on behalf of affiliated funds.^[3]
Public filings and proxy statements are the primary sources documenting board service, beneficial ownership and Section 16 reporting for Mr. Baker’s activities.^[2]

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2017-02-17	INCYINCYTE CORPA Award	Director, 10% Owner	AAward	+4.49M sh	—	—	24,245,586
2017-02-17	INCYINCYTE CORPA Award	Director, 10% Owner	AAward	+122K sh	—	—	767,095
2017-02-17	INCYINCYTE CORP · 0.375% Convertible Senior Note due 2018D Disposition to Issuer	Director, 10% Owner	DDisposition to Issuer	−25M sh	—	—	0
2017-02-17	INCYINCYTE CORPA Award	Director, 10% Owner	AAward	+112K sh	—	—	645,423
2017-02-17	INCYINCYTE CORPA Award	Director, 10% Owner	AAward	+503K sh	—	—	4,353,957
2017-02-17	INCYINCYTE CORP · 1.25% Convertible Senior Note due 2020D Disposition to Issuer	Director, 10% Owner	DDisposition to Issuer	−25M sh	—	—	0
2017-02-17	INCYINCYTE CORPA Award	Director, 10% Owner	AAward	+4.9M sh	—	—	29,141,653
2017-02-17	INCYINCYTE CORP · 1.25% Convertible Senior Note due 2020D Disposition to Issuer	Director, 10% Owner	DDisposition to Issuer	−243M sh	—	—	0
2017-02-17	INCYINCYTE CORP · 0.375% Convertible Senior Note due 2018D Disposition to Issuer	Director, 10% Owner	DDisposition to Issuer	−228M sh	—	—	0
2017-02-17	INCYINCYTE CORPA Award	Director, 10% Owner	AAward	+491K sh	—	—	3,851,178
2017-02-17	INCYINCYTE CORP · 1.25% Convertible Senior Note due 2020D Disposition to Issuer	Director, 10% Owner	DDisposition to Issuer	−6.05M sh	—	—	0
2017-02-17	INCYINCYTE CORP · 0.375% Convertible Senior Note due 2018D Disposition to Issuer	Director, 10% Owner	DDisposition to Issuer	−5.67M sh	—	—	0
2017-01-03	Aceragen, Inc.A Award	10% Owner	AAward	+14.2K sh	$1.50	+$21.3K	1,017,950
2017-01-03	Aceragen, Inc.A Award	10% Owner	AAward	+14.2K sh	$1.50	+$21.3K	9,323,502
2017-01-03	Aceragen, Inc.A Award	10% Owner	AAward	+14.2K sh	$1.50	+$21.3K	125,179
2016-12-30	INCYINCYTE CORPA Award	Director, 10% Owner	AAward	+189 sh	$100.27	+$19K	19,758,174
2016-12-30	INCYINCYTE CORPA Award	Director, 10% Owner	AAward	+189 sh	$100.27	+$19K	533,909
2016-12-30	INCYINCYTE CORPA Award	Director, 10% Owner	AAward	+189 sh	$100.27	+$19K	3,359,840
2016-10-07	Aceragen, Inc.P Purchase	10% Owner	PPurchase	+2.93M sh	$2.00	+$5.86M	9,309,333
2016-10-07	Aceragen, Inc.P Purchase	10% Owner	PPurchase	+321K sh	$2.00	+$643K	1,003,781
2016-10-03	Aceragen, Inc.A Award	10% Owner	AAward	+8,299 sh	$2.56	+$21.2K	6,380,737
2016-10-03	Aceragen, Inc.A Award	10% Owner	AAward	+8,299 sh	$2.56	+$21.2K	111,010
2016-10-03	Aceragen, Inc.A Award	10% Owner	AAward	+8,299 sh	$2.56	+$21.2K	682,377
2016-09-30	INCYINCYTE CORPA Award	Director, 10% Owner	AAward	+201 sh	$94.29	+$19K	533,720
2016-09-30	INCYINCYTE CORPA Award	Director, 10% Owner	AAward	+201 sh	$94.29	+$19K	3,359,651
2016-09-30	INCYINCYTE CORPA Award	Director, 10% Owner	AAward	+201 sh	$94.29	+$19K	19,757,985
2016-07-01	Aceragen, Inc.A Award	10% Owner	AAward	+13K sh	$1.63	+$21.3K	6,372,438
2016-07-01	Aceragen, Inc.A Award	10% Owner	AAward	+13K sh	$1.63	+$21.3K	674,078
2016-07-01	Aceragen, Inc.A Award	10% Owner	AAward	+13K sh	$1.63	+$21.3K	102,711
2016-06-30	INCYINCYTE CORPA Award	Director, 10% Owner	AAward	+237 sh	$79.98	+$19K	19,757,784
2016-06-30	INCYINCYTE CORPA Award	Director, 10% Owner	AAward	+237 sh	$79.98	+$19K	533,519
2016-06-30	INCYINCYTE CORPA Award	Director, 10% Owner	AAward	+237 sh	$79.98	+$19K	3,359,450
2016-06-13	Aceragen, Inc.Non-Qualified Stock Option (right to buy)A Award	10% Owner	AAward	+70K sh	—	—	70,000
2016-05-27	INCYINCYTE CORP · Non-Qualified Stock Options (right to buy)A Award	Director, 10% Owner	AAward	+15K sh	—	—	15,000
2016-04-01	Aceragen, Inc.A Award	10% Owner	AAward	+10.8K sh	$1.97	+$21.3K	661,040
2016-04-01	Aceragen, Inc.A Award	10% Owner	AAward	+10.8K sh	$1.97	+$21.3K	89,673
2016-04-01	Aceragen, Inc.A Award	10% Owner	AAward	+10.8K sh	$1.97	+$21.3K	6,359,400
2016-03-31	INCYINCYTE CORPA Award	Director, 10% Owner	AAward	+262 sh	$72.47	+$19K	3,359,213
2016-03-31	INCYINCYTE CORPA Award	Director, 10% Owner	AAward	+262 sh	$72.47	+$19K	533,282
2016-03-31	INCYINCYTE CORPA Award	Director, 10% Owner	AAward	+262 sh	$72.47	+$19K	19,757,547
2016-03-17	INCYINCYTE CORPP Purchase	Director, 10% Owner	PPurchase	+13.9K sh	$61.38	+$855K	3,349,130
2016-03-17	INCYINCYTE CORPP Purchase	Director, 10% Owner	PPurchase	+2,250 sh	$60.95	+$137K	3,332,534
2016-03-17	INCYINCYTE CORPP Purchase	Director, 10% Owner	PPurchase	+20.7K sh	$60.95	+$1.26M	19,514,711
2016-03-17	INCYINCYTE CORP · Non-Qualified Stock Options (right to buy)M Exercise/Conversion	Director, 10% Owner	MExercise/Conversion	−20K sh	—	—	0
2016-03-17	INCYINCYTE CORPP Purchase	Director, 10% Owner	PPurchase	+2,660 sh	$61.03	+$162K	3,335,194
2016-03-17	INCYINCYTE CORPP Purchase	Director, 10% Owner	PPurchase	+97.5K sh	$60.85	+$5.93M	19,494,052
2016-03-17	INCYINCYTE CORPP Purchase	Director, 10% Owner	PPurchase	+90.2K sh	$62.59	+$5.64M	19,757,285
2016-03-17	INCYINCYTE CORP · Non-Qualified Stock Options (right to buy)M Exercise/Conversion	Director, 10% Owner	MExercise/Conversion	−20K sh	—	—	0
2016-03-17	INCYINCYTE CORPM Exercise/Conversion	Director, 10% Owner	MExercise/Conversion	+20K sh	$3.86	+$77.2K	19,396,568
2016-03-17	INCYINCYTE CORPM Exercise/Conversion	Director, 10% Owner	MExercise/Conversion	+20K sh	$3.86	+$77.2K	533,020

Recent filings

Accepted (ET)
Feb 224
INCYTE CORP0001638599-17-000213
SEC(opens sec.gov)
Jan 54
IDERA PHARMACEUTICALS, INC.0001638599-17-000048
SEC(opens sec.gov)
Jan 44
INCYTE CORP0001638599-17-000024
SEC(opens sec.gov)
Oct 114
IDERA PHARMACEUTICALS, INC.0001638599-16-001463
SEC(opens sec.gov)

Companies

Address

860 WASHINGTON STREET, 3RD FLOOR

NEW YORK, NY, 10014